Literature DB >> 953977

Second-look operation in ovarian carcinoma: postchemotherapy.

J P Smith, G Delgado, F Rutledge.   

Abstract

One hundred and three patients with advanced ovarian cancer underwent a second-look operation following chemotherapy. Patients should have ten or more courses of chemotherapy before second-look operation. Those patients with no evidence of disease at second laparotomy should discontinue their chemotherapy. Patients who continued chemotherapy after the second-look operation did better than those who were treated with radiation after surgery. Only patients with clinical remission benefit from the second-look procedure. Advantages of second-look operations following chemotherapy are discussed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 953977     DOI: 10.1002/1097-0142(197609)38:3<1438::aid-cncr2820380351>3.0.co;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Obstetrics and gynecology-epitomes of progress: a second-look operation in the management of patients with carcinoma of the ovary.

Authors:  T W Castaldo
Journal:  West J Med       Date:  1980-03

2.  Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.

Authors:  Peter G Rose; James J Java; Mark A Morgan; Angeles Alvarez-Secord; Joshua P Kesterson; Frederick B Stehman; David P Warshal; William T Creasman; Parviz Hanjani; Robert T Morris; Larry J Copeland
Journal:  Gynecol Oncol       Date:  2016-09-28       Impact factor: 5.482

3.  A study of the treatment of ovarian carcinoma.

Authors:  H Pickel
Journal:  Arch Gynecol       Date:  1983

4.  Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trial.

Authors:  C Sessa; G Bolis; N Colombo; M D'Incalci; B Mermillod; I Valente; C Mangioni
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

5.  Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker.

Authors:  P A Canney; M Moore; P M Wilkinson; R D James
Journal:  Br J Cancer       Date:  1984-12       Impact factor: 7.640

6.  Second look laparotomy in the management of epithelial cell carcinoma of the ovary.

Authors:  G M Mead; C J Williams; F R MacBeth; I E Boyd; J M Whitehouse
Journal:  Br J Cancer       Date:  1984-08       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.